Abstract
Although neurodegenerative diseases exhibit distinct pathologies, such as affected neuronal cell population, age of onset, and pathological symptoms, overlapping characteristics can be observed at the cellular level. In particular, several neurodegenerative diseases display defects in intracellular vesicular trafficking. Here we discuss the range of cellular phenotypes observed in two rare neurodegenerative diseases, Niemann-Pick Type C and Huntingtons Disease, both of which involve vesicular trafficking defects that may contribute to neuronal cell death. In NPC, the primary defect is cholesterol and glycosphingolipid accumulation, but NPC mutant cells display widespread trafficking alterations. In HD, protein aggregates are a hallmark feature, but HD cells also exhibit changes in vesicular traffic, including axonal transport and early endosomal trafficking, that likely impact neuronal cell viability. Here we discuss current therapies that seek to address cellular defects in NPC and HD and describe areas of investigation that may lead to new therapeutic treatment.
Current Drug Targets
Title: Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking
Volume: 10 Issue: 7
Author(s): J. K. Schweitzer, J. P. Krivda and C. D'Souza-Schorey
Affiliation:
Abstract: Although neurodegenerative diseases exhibit distinct pathologies, such as affected neuronal cell population, age of onset, and pathological symptoms, overlapping characteristics can be observed at the cellular level. In particular, several neurodegenerative diseases display defects in intracellular vesicular trafficking. Here we discuss the range of cellular phenotypes observed in two rare neurodegenerative diseases, Niemann-Pick Type C and Huntingtons Disease, both of which involve vesicular trafficking defects that may contribute to neuronal cell death. In NPC, the primary defect is cholesterol and glycosphingolipid accumulation, but NPC mutant cells display widespread trafficking alterations. In HD, protein aggregates are a hallmark feature, but HD cells also exhibit changes in vesicular traffic, including axonal transport and early endosomal trafficking, that likely impact neuronal cell viability. Here we discuss current therapies that seek to address cellular defects in NPC and HD and describe areas of investigation that may lead to new therapeutic treatment.
Export Options
About this article
Cite this article as:
Schweitzer K. J., Krivda P. J. and D'Souza-Schorey C., Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking, Current Drug Targets 2009; 10 (7) . https://dx.doi.org/10.2174/138945009788680437
DOI https://dx.doi.org/10.2174/138945009788680437 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Other Proteins Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Current Molecular Medicine Recent Advances in the Study of Glycosphingolipids
Current Pharmaceutical Biotechnology Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews PLA2G6 Mutations and Other Rare Causes of Neurodegeneration with Brain Iron Accumulation
Current Drug Targets The Role of Peroxidation of Mitochondrial Membrane Phospholipids in Pancreatic β -Cell Failure
Current Diabetes Reviews Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline
Current Medicinal Chemistry Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Current Protein & Peptide Science Pantothenate Kinase-Associated Neurodegeneration
Current Drug Targets α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Aceruloplasminemia
Current Drug Targets Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes
Current Diabetes Reviews Group VI Phospholipases A2: Homeostatic Phospholipases with Significant Potential as Targets for Novel Therapeutics
Current Drug Targets Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry